gastroduodenal mucosa,`~their role during long term treatment in predisposing to peptic ulcer disease and clinically important complications remains uncertain.4'" Common criticisms of existing studies include inadequate design,' investigating young volunteers rather than older patients, examining acute and not chronic injury, and focusing attention on aspirin.-" Interpretation is particularly clouded by the prevalence of unsuspected (clinically irrelevant?) gastroduodenal lesions observed endoscopically in patients who take non-steroidal anti-inflammatory drugs, irrespective of their rheumatic condition."' Well designed case-control studies have nevertheless associated non-steroidal anti-inflammatory drugs with gastroduodenal (and ileal and colonic) bleeding and perforation,'1-2l though ranking of toxicity among such drugs has proved problematic.`Such difficulties, with the need to distinguish clearly individual and population risks, have been extensively reviewed. ' Whether to start treatment Controversy, however, surrounds continuing or starting treatment with non-steroidal anti-inflammatory drugs in patients with current or past peptic ulcer disease. There are four principal concerns.
Firstly, should non-steroidal anti-inflammatory drugs be given at all? Even after considering the above, some patients with chronic locomotor symptoms find non-steroidal anti-inflammatory drugs undeniably beneficial, and their quality of life is considerably diminished when they are withdrawn. Although the Committee on Safety of Medicines states that nonsteroidal anti-inflammatory drugs should not be given to patients with active peptic ulceration,2 such official advice, predominantly reflecting expectation bias,23 would result in withdrawal of such drugs in up to 30% of patients with chronic rheumatic disease. 6 The few studies available, however, show that continuing treatment with the drugs little influences the rates of healing obtained with conventional anti-ulcer treatment'6 24.27: indeed, ulcers may heal spontaneously despite continuing non-steroidal anti-inflammatory drugs.28 If appropriate non-steroidal anti-inflammatory drugs should therefore still be considered.
Secondly, which non-steroidal anti-inflammatory drug should be prescribed? Salicylate and indomethacin should probably be avoided in peptic ulceration because of their additional direct mucosal toxicity246 (in the United Kingdom salicylate is rarely prescribed for arthritis anyway, and indomethacin should be Gastric erosions as an incidentalfinding in a patient without dyspepsia avoided in elderly patients because of frequent side effects in the central nervous system and kidney). Although theoretically attractive, pro-drugs, suppositories, enteric coated or delayed release formulations afford no significant clinical advantage7 10291-systemic rather than local effects remain important.23 Newer non-steroidal anti-inflammatory drugs that spare prostaglandin E2 merit further investigation.' Ibuprofen, especially in low doses seems to be particularly safe,722 but appreciable variation between patients dictates that the choice of drug lies with the patient-taking the doctor's preferred non-steroidal anti-inflammatory drug is pointless if it is ineffective. Usual precautions about prescribing-for example, appropriate dosage and one non-steroidal anti-inflammatory drug onlyobviously apply.
Thirdly, which anti-ulcer treatment should be used and for how long? Acute mucosal injury associated with non-steroidal anti-inflammatory drugs is certainly reduced by H2 antagonists (independently of inhibiting the secretion of acid30), sucralfate, and synthetic prostaglandin analogues,3034 but long term data in patients are sparse. Most long term studies report good rates of healing with cimetidine or ranitidine,'6242627 though their usefulness in this situation has been questioned.283536 Although mucosal protection rather than acid reduction seems theoretically more appropriate,' good clinical studies to determine the optimum regimens for both healing and preventing relapse in patients receiving long term treatment with non-steroidal anti-inflammatory drugs are still awaited.
Fourthly, how should progress be monitored? This begs the question of what is being treated. Complications undoubtedly require correction, but poor correlation of symptoms, occult blood loss, and endoscopic findings78 2 14 16 means that one cannot be used to monitor another. Occult blood loss is particularly unhelpful,37 and undue emphasis on endoscopic appearance may well prove inappropriate.
Conclusions
The high prevalence of unsuspected peptic ulcer disease'2-'6 strongly suggests that in most cases no clinical consequences arise from untreated peptic ulcer disease during continuing treatment with nonsteroidal anti-inflammatory drugs. What we need to know is which factors (other than being old and female) determine the development of complications so that they (for example, individual non-steroidal antiinflammatory drugs) may be eliminated and prophylactic approaches tested in high risk patients taking the drugs. Results of well designed studies that answer such questions and provide management guidelines are eagerly awaited.
